Consortium IO Logo

CONSORTIUM-IO (NCT04208958) was a first-in-patient clinical trial to evaluate the safety, tolerability and clinical activity of VE800 in combination with Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo® (nivolumab), as measured by the confirmed overall response rate, in addition to other parameters, in patients with select types of advanced or metastatic cancer.

CONSORTIUM-IO is currently not enrolling patients.

For additional study information, please visit  

If you have questions about the study, please email: